Insider Buying: Zura Bio Limited (NASDAQ:ZURA) Director Buys 159,744 Shares of Stock

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi purchased 159,744 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the transaction, the director now directly owns 777,384 shares in the company, valued at $2,433,211.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Zura Bio Trading Up 9.4 %

NASDAQ ZURA opened at $3.62 on Friday. The business’s 50 day moving average is $3.19 and its two-hundred day moving average is $4.03. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $14.00.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer restated an “outperform” rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.40.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Forefront Analytics LLC increased its position in Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after purchasing an additional 6,765 shares during the period. Armistice Capital LLC boosted its stake in shares of Zura Bio by 15.4% during the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares in the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Zura Bio during the 3rd quarter worth approximately $65,000. Eisler Capital US LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth approximately $660,000. Finally, Silverarc Capital Management LLC boosted its stake in shares of Zura Bio by 152.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.